Invacare
Market Cap
US$207.8m
Last Updated
2019/10/19 23:39 UTC
Data Sources
Company Financials +
Executive Summary
Invacare Corporation, together with its subsidiaries, designs, manufactures, distributes, and exports medical equipment for use in home health care, retail, and extended care markets worldwide.
Snowflake
Fundamentals
Adequate balance sheet and overvalued.
Similar Companies
Share Price & News
How has Invacare's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-11.7%
IVC
1.9%
US Medical Equipment
0.4%
US Market
1 Year Return
-56.4%
IVC
15.6%
US Medical Equipment
6.9%
US Market
Return vs Industry: IVC underperformed the US Medical Equipment industry which returned 15.6% over the past year.
Return vs Market: IVC underperformed the US Market which returned 6.9% over the past year.
Shareholder returns
| IVC | Industry | Market | |
|---|---|---|---|
| 7 Day | -11.7% | 1.9% | 0.4% |
| 30 Day | -16.1% | -1.6% | -1.2% |
| 90 Day | 38.3% | 0.01% | -0.4% |
| 1 Year | -56.0%-56.4% | 16.5%15.6% | 9.3%6.9% |
| 3 Year | -39.7%-40.7% | 72.1%66.9% | 45.8%36.4% |
| 5 Year | -58.1%-59.0% | 125.8%100.8% | 62.9%45.1% |
Price Volatility Vs. Market
How volatile is Invacare's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
How Much Are Invacare Corporation (NYSE:IVC) Insiders Spending On Buying Shares?1 month ago | Simply Wall St
Health Check: How Prudently Does Invacare (NYSE:IVC) Use Debt?1 month ago | Simply Wall St
The Invacare (NYSE:IVC) Share Price Is Down 66% So Some Shareholders Are Wishing They SoldValuation
Is Invacare undervalued compared to its fair value and its price relative to the market?
0.63x
Price to Book (PB) ratio
Share Price vs. Fair Value
Undervalued: IVC ($6.17) is trading above our estimate of fair value ($0.25)
Significantly Undervalued: IVC is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: IVC is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: IVC is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
Low PEG Ratio: Insufficient data to calculate IVC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IVC is good value based on its PB Ratio (0.6x) compared to the US Medical Equipment industry average (3.8x).
Next Steps
Future Growth
How is Invacare forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
113.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IVC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IVC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IVC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IVC's revenue (2.9% per year) is forecast to grow slower than the US market (7.2% per year).
High Growth Revenue: IVC's revenue (2.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: Insufficient data to determine if IVC's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Invacare performed over the past 5 years?
-1.0%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: IVC is unprofitable, and losses have increased over the past 5 years at a rate of -1% per year.
Accelerating Growth: Unable to compare IVC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IVC is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).
Return on Equity
High ROE: IVC has a negative Return on Equity (-12.01%), as it is currently unprofitable.
Return on Assets
ROA vs Industry: IVC is currently unprofitable, so its Return on Assets is negative.
Return on Capital Employed
ROCE Improving: IVC is currently unprofitable, so its Return on Capital Employed is negative.
Next Steps
Financial Health
How is Invacare's financial position?
Financial Position Analysis
Short Term Liabilities: IVC's short term assets ($368.0M) exceeds its short term liabilities ($193.9M)
Long Term Liabilities: IVC's short term assets (368.0M) exceeds its long term liabilities (341.8M)
Debt to Equity History and Analysis
Debt Level: IVC's debt to equity ratio (70.3%) is considered high
Reducing Debt: IVC's debt to equity ratio has increased from 8.7% to 70.3% over the past 5 years.
Balance Sheet
Inventory Level: IVC has a high level of physical assets or inventory.
Debt Coverage by Assets: IVC's debt is covered by short term assets (assets are 1.576350x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IVC has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: IVC has sufficient cash runway for 2.572627 years if free cash flow continues to grow at historical rates of 4.1% each year.
Next Steps
Dividend
What is Invacare's current dividend yield, its reliability and sustainability?
0.81%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: IVC's dividend (0.81%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.45%).
High Dividend: IVC's dividend (0.81%) is low compared to the top 25% of dividend payers in the US market (3.73%).
Stable Dividend: IVC is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: IVC is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: IVC is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IVC's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Invacare's salary, the management and board of directors tenure and is there insider trading?
2.4yrs
Average management tenure
CEO
Matt Monaghan (51yo)
4.5yrs
Tenure
US$5,325,390
Compensation
Mr. Mathew E. Monaghan, also known as Matt, has been the Chief Executive Officer and President of Invacare Corporation since April 01, 2015 and has been its Chairman of the Board since May 14, 2015. Mr. Mo ...
CEO Compensation Analysis
Compensation vs. Market: Matt's total compensation ($USD5.33M) is above average for companies of similar size in the US market ($USD1.16M).
Compensation vs Earnings: Matt's compensation has been consistent with company performance over the past year.
Management Age and Tenure
2.4yrs
Average Tenure
52yo
Average Age
Experienced Management: IVC's management team is considered experienced (2.4 years average tenure).
Board Age and Tenure
3.4yrs
Average Tenure
56yo
Average Age
Experienced Board: IVC's board of directors are considered experienced (3.4 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chief Financial Officer Senior VP & CFO |
| Shares | 6,500 |
| Max Price | US$5.52 |
| Entity | Individual |
| Shares | 9,000 |
| Max Price | US$5.42 |
| Entity | Individual |
| Role | Chief Executive Officer Chairman |
| Shares | 13,750 |
| Max Price | US$7.26 |
Ownership Breakdown
Management Team
Matt Monaghan (51yo)
Chairman
- Tenure: 4.5yrs
- Compensation: US$5.33m
Anthony LaPlaca (61yo)
Senior VP
- Tenure: 10.8yrs
- Compensation: US$816.09k
Ralf Ledda (51yo)
Senior VP & GM of EMEA
- Tenure: 2.9yrs
- Compensation: US$848.30k
Kathleen Leneghan (56yo)
Senior VP & CFO
- Tenure: 1.9yrs
- Compensation: US$1.19m
Darcie Karol (52yo)
Senior Vice President of Human Resources
- Tenure: 1.3yrs
- Compensation: US$472.46k
Lois Lee
Director of Treasury and Investor Relations
- Tenure: 0yrs
Joost Beltman
Vice President of Sales & Marketing for North America
- Tenure: 0.3yrs
Board Members
C. Harris (63yo)
Lead Independent Director
- Tenure: 7.4yrs
- Compensation: US$207.66k
Diana Ferguson (55yo)
Independent Director
- Tenure: 1.3yrs
- Compensation: US$110.50k
Susan Alexander (62yo)
Independent Director
- Tenure: 2.8yrs
- Compensation: US$187.66k
Baiju Shah (47yo)
Independent Director
- Tenure: 8.4yrs
- Compensation: US$192.66k
Matt Monaghan (51yo)
Chairman
- Tenure: 4.5yrs
- Compensation: US$5.33m
Julie Beck (57yo)
Director
- Tenure: 0.08yrs
Marc Gibeley (54yo)
Independent Director
- Tenure: 3.9yrs
- Compensation: US$177.66k
Petra Danielsohn-Weil (59yo)
Independent Director
- Tenure: 1.4yrs
- Compensation: US$136.37k
Company Information
Invacare Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Invacare Corporation
- Ticker: IVC
- Exchange: NYSE
- Founded: 1885
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$207.768m
- Shares outstanding: 33.67m
- Website: https://www.invacare.com
Number of Employees
Location
- Invacare Corporation
- One Invacare Way
- Elyria
- Ohio
- 44035
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| IVC | NYSE (New York Stock Exchange) | Yes | Common Shares | US | USD | May 1984 |
| IV3 | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | May 1984 |
Biography
Invacare Corporation, together with its subsidiaries, designs, manufactures, distributes, and exports medical equipment for use in home health care, retail, and extended care markets worldwide. The company ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/19 23:39 |
| End of Day Share Price | 2019/10/18 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.